These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1398293)

  • 1. Danazol therapy in myelodysplastic syndromes.
    Pozzato G; Franzin F; Moretti M; Campanacci L
    Haematologica; 1992; 77(1):96. PubMed ID: 1398293
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic efficacy of danazol in myelodysplastic syndromes.
    Marini B; Bassan R; Barbui T
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1481-9. PubMed ID: 3181270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danazol and myelodysplastic syndromes.
    Kornberg A; Yona R; Iuklea S; Kaufman S
    Ann Intern Med; 1986 Mar; 104(3):445-6. PubMed ID: 3946991
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized study of danazol vs. placebo in myelodysplastic syndromes.
    Avilés A; Rubio ME; Gómez J; Medina ML; González-Llaven J
    Arch Invest Med (Mex); 1989; 20(2):183-8. PubMed ID: 2690768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of myelodysplastic syndromes with danazol].
    Aviles A; García LD; Romero N; Tripp F; González-Llaven J
    Arch Invest Med (Mex); 1988; 19(1):73-7. PubMed ID: 3228341
    [No Abstract]   [Full Text] [Related]  

  • 6. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
    Chan G; DiVenuti G; Miller K
    Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine in the treatment of myelodysplastic syndromes.
    Del Río Garma J; Fernandez Lago C; Batlle Fonrodona FJ
    Haematologica; 1997; 82(5):639-40. PubMed ID: 9407744
    [No Abstract]   [Full Text] [Related]  

  • 8. [Danazol in the treatment of acute leukemic transformation of myelodysplastic syndromes].
    Sans-Sabrafen J; Martín Casellas E; Salinas Argente R
    Med Clin (Barc); 1987 Nov; 89(17):756. PubMed ID: 3695720
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of myelodysplastic syndromes aside from clinical studies].
    Lengfelder E; Hehlmann R
    Dtsch Med Wochenschr; 1995 Nov; 120(44):1527. PubMed ID: 7588024
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of 76 patients with myelodysplastic syndromes treated with danazol.
    Chabannon C; Molina L; Pégourié-Bandelier B; Bost M; Léger J; Hollard D
    Cancer; 1994 Jun; 73(12):3073-80. PubMed ID: 8200005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. r-huEPO in MDS: the day after.
    Marqués da Costa R
    Sangre (Barc); 1994 Aug; 39(4):298-9. PubMed ID: 7985061
    [No Abstract]   [Full Text] [Related]  

  • 12. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy.
    Kondo H; Iseki T; Goto S; Takaso T; Ohto M; Okuda K
    Int J Hematol; 1992 Jun; 55(3):293-300. PubMed ID: 1498320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome.
    Motomura S; Fujisawa S; Tsunooka S; Fujimaki K; Mohri H; Okubo T
    Am J Hematol; 1996 Oct; 53(2):143-4. PubMed ID: 8892744
    [No Abstract]   [Full Text] [Related]  

  • 16. Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes.
    Viniou N; Plata E; Terpos E; Variami E; Meletis J; Vaiopoulos G; Loukopoulos D; Chatzidimitriou G; Yataganas X
    Acta Haematol; 2002; 107(4):234-6. PubMed ID: 12053153
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of eicosapentaenoic acid in patients with refractory myelodysplastic syndrome.
    Okamoto T; Okada M; Wakae T; Takatsuka H; Kakishita E
    Am J Hematol; 2002 Dec; 71(4):350-1. PubMed ID: 12447972
    [No Abstract]   [Full Text] [Related]  

  • 18. Danazol in the treatment of myelodysplastic syndromes.
    Buzaid AC; Garewal HS; Lippman SM; Durie BG; Katakkar SB; Greenberg BR
    Eur J Haematol; 1987 Oct; 39(4):346-8. PubMed ID: 3319676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
    Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
    Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [15 patients with myelodysplastic syndrome].
    Dimova R; Apostolov P; Popova L
    Vutr Boles; 1989; 28(3):96-100. PubMed ID: 2773468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.